Abstract This article was conducted to review the diagnostic performance of Tc-labeled methylene diphosphonate in evaluating patients with metastatic bone tumor, updating a previous meta-analysis on this topic. We performed an updated metaanalysis of all available studies addressing the diagnostic accuracy of F-fluoride PET/CT, (2) bone scintigraphy, (3) bone metastasis, metastatic bone tumor, without language restriction. We constructed summary receiver operating characteristic curves using hierarchical regression models. Effective dose and cost-effectiveness, estimated from the data of the enrolled studies, were also compared between 
Tc-labeled methylene diphosphonate in evaluating patients with metastatic bone tumor, updating a previous meta-analysis on this topic. We performed an updated metaanalysis of all available studies addressing the diagnostic accuracy of 18 F-fluoride PET, 18 F-fluoride PET/CT, planar BS, and planar BS plus SPECT for detecting metastatic bone tumor. The Medline (from 1966 to November, 2012), SCO-PUS, and Biological Abstracts databases were searched using a search algorithm based on combinations of the terms: (1) 18 F-fluoride, 18 F-fluoride PET, or 18 F-fluoride PET/CT, (2) bone scintigraphy, (3) bone metastasis, metastatic bone tumor, without language restriction. We constructed summary receiver operating characteristic curves using hierarchical regression models. Effective dose and cost-effectiveness, estimated from the data of the enrolled studies, were also compared between 18 F-fluoride PET or PET/CT and planar BS or planar BS plus SPECT. Comparison of all the studies with data on 18 F-fluoride PET or PET/CT showed sensitivity and specificity values of 91.9-and 97.1 % on patient-based analyses and 83.3 and 86.8 % on lesion-based analyses. The Az values of 18 F-fluoride PET or PET/CT were 0.987 on a patient basis and 0.894 on a lesion basis, whereas those of BS or BS plus SPECT were 0.867 on a patient basis and 0.854 on a lesion basis. However, 18 F-fluoride PET or PET/CT showed poorer estimated effective dose and average cost-effectiveness ratio when compared with the values recorded for planar BS or planar BS plus SPECT. 18 F-fluoride PET or PET/CT showed excellent diagnostic performance for the detection of metastatic bone tumor, but the estimated effective dose and the average cost-effectiveness ratio were poorer than the values recorded with planar BS or planar BS plus SPECT. The question of whether there is an incremental diagnostic improvement with
Introduction

Bone metastases
The presence of bone metastases is an important prognostic factor in patients with cancer because bone is a common site of distant metastases in patients with advanced stage disease. Bone metastases cause much of the morbidity and disability in patients with cancer despite recent advances in treatment regimens. Proper evaluation of bone metastases and early detection of occult bone metastases are essential for correct treatment decisions and improved outcome.
Imaging diagnosis
The extent of physiological impairment associated with bone metastases does not necessarily correlate with the degree of morphological changes identified by imaging; that is, some patients with extensive bone metastases may be asymptomatic, whereas others with focal bone destruction evident on roentgenogram may have significant physiological impairment. The roentgenogram is useful for detection of focal lesions with bone destruction or fracture; however, it is inadequate for screening for diffuse bone metastases in clinical practice [1] . In patients presenting an increased risk of focal metastases on physical examination, particularly those with poor performance status, additional studies are usually required. The CT scan is more sensitive and specific than the roentgenogram for the detection of focal bone metastases [1] . It is used mainly for the early recognition of bone metastases with destruction or asymptomatic fracture in at-risk individuals, thereby precluding the necessity for surgical procedure to treat for activity of daily living and to identify unexplained bone lesion.
Bone scintigraphy (BS) using 99m Tc-labeled methylene diphosphonate ( 99m Tc-MDP) and magnetic resonance imaging (MRI) plays an important role in detecting occult bone metastases that are missed by physical examination. However, the sensitivity of BS alone is not satisfactory because of the technique's limited spatial resolution [1] . Single-photon emission computed tomography (SPECT) helps to clarify equivocal cases identified on BS. It has been proposed that in patients with poor performance status, BS has a lower sensitivity for detecting bone metastases when compared with whole-body MRI with diffusion-weighted sequences. Although the diagnostic accuracy of whole-body MRI with diffusion-weighted sequences is desirable to detect metastatic bone tumor, this technique is available only for limited clinical studies to detect occult bone metastases [2] . 18 
F-FDG PET/CT
Fluorine-18-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) has been shown to be substantially more accurate than conventional imaging for assessing bone metastases in advanced cancer [1] . Although PET has proved to be an effective tool in the management of advanced cancer, it provides limited information on morphological abnormalities in bone. The presence of four different types of bone metastasis: lytic/lucent, blastic/sclerotic, mixed, and without any morphological abnormalities, often complicates the assessment of bone metastases. Accurately co-registered functional and morphological data sets are generated by integrated PET/CT imaging systems, and these combined functional and morphological systems have given promising results in terms of diagnosis of skeletal metastases. However, despite the increasing use of integrated PET/CT in the management of advanced cancer, the clinical utility of combined assessment of 18 F-FDG avidity and morphological changes in bone metastases of advanced cancer has not been fully elucidated. 18 
F-FDG PET/MRI
The recent introduction of integrated whole-body PET/ MRI has given us a new metabolic-anatomical imaging technique for application in clinical practice [3] [4] [5] . PET/ MRI seems to be highly accurate in detecting bone metastases for which MRI has traditionally been favored. By adding functional MRI to PET data, PET/MRI may further improve diagnostic accuracy in the differentiation between malignant and benign lesions. This hypothesis will have to be assessed in future studies through comparison with the results of conventional imaging. With regard to large bone metastases, PET/MRI does not seem to offer a considerable benefit over PET/CT, although it provides a new whole-body staging method [3] . Small bone metastases or bone marrow metastases can be easily detected by integrated whole-body PET/MRI [5] . Involvement of bone marrow in patients with hematological malignancies will also be assessed in future studies. 18 F-fluoride definition 18 F-fluoride is a molecular imaging agent used to identify new bone formation. In this environment, the deposition of 18 F-fluoride as fluoroapatite in blastic and lytic/lucent lesions, which is due to the fact that 18 F-fluoride ion exchanges with hydroxyl groups in hydroxyapatite crystal, reflects increased blood flow and bone turnover [6] . This tracer was approved by the U.S. Food and Drug Administration (FDA) in 1972. However, it was subsequently listed in the Orange Book for continued drug products by the FDA. 18 F-fluoride is manufactured and distributed by authorized user prescription under state pharmacy laws. The combination of 18 F-fluoride and PET/CT allows crosssectional functional and anatomical imaging for diagnosis of bone metastases, because PET/CT can include the entire body from the top of the head to the toes.
Possible clinical indications
18 F-fluoride PET or PET/CT can be widely used to identify skeletal lesions other than metastases, and can localize and determine the extent of disease. There are many possible indications for 18 F-fluoride PET or PET/CT because sufficient information exists to recommend the following situations: back pain and otherwise unexplained bone pain, child abuse, osteomyelitis, trauma, inflammatory and degenerative arthritis, avascular necrosis, osteonecrosis of the mandible, condylar hyperplasia, metabolic bone disease, Paget disease, bone graft viability, complications of prosthetic joints, reflex sympathetic dystrophy or complex regional pain syndrome I and II, evaluation of the distribution of osteoblastic activity before administration of therapeutic radiopharmaceuticals for bone pain, atherosclerosis, and hyperostosis and osseous involvement of meningioma [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . 18 F-fluoride PET or PET/CT in the detection of bone metastases 18 F-fluoride PET has shown favorable overall accuracy in the detection of bone metastases using pathology as the reference standard [26] . It has been suggested that 18 Ffluoride PET might be more accurate than BS in identifying bone metastases because it is considered to have greater spatial resolution [26] [27] [28] [29] [30] . The increasing use of integrated PET/CT reveals that this modality is useful for the purpose of detecting bone metastases, because it can provide information on 18 F-fluoride avidity and morphological changes in lesions [26] [27] [28] [29] [30] . Therefore, when compared with conventional imaging, 18 F-fluoride PET or PET/CT is considered to show a more accurate diagnostic performance in detecting bone metastases. However, results of previous studies have limited external validity: several studies were inconclusive because they had small sample sizes, compared various combinations of imaging modalities, and used a variety of methods for determining the diagnostic performance of 18 F-fluoride PET or PET/ CT.
Procedure/specification of 18 F-fluoride PET or PET/CT study
Preparation and precautions
Examinations should be avoided in pregnant women, unless the potential benefits outweigh the radiation risk to the mother and fetus [26] . Prior to the clinical study, patients should be well hydrated to promote rapid excretion of the radiopharmaceutical, to decrease radiation dose, and to improve image quality [27] . Intense tracer activity in the urinary bladder degrades image quality and can confound interpretation of findings in the pelvis. Hydration and a loop diuretic, without or with bladder catheterization, may be used to reduce accumulated urinary tracer activity in the bladder. Patients should drink two or more 224-mL glasses of water within 1 h before the examination, and another two or more 224-mL glasses of water after administration of 18 F-fluoride, according to the SNM guideline [26] . Patients do not need to fast and may take their usual medications. The impact of treatments such as chemotherapy and radiotherapy on the uptake of 18 F-fluoride is yet to be determined.
Accreditation of PET or PET/CT scanners and determination of the data acquisition protocol
The Core Laboratory should be used to determine whether PET or PET/CT data are acquired under appropriate conditions and whether appropriate QC is implemented for the scanner. To ascertain the validity of the acquisition protocol and image reconstruction parameters, phantom experiments should be conducted in compliance with the aforementioned guideline [26] . The items investigated include (1) scanner manufacturer and model type, (2) frequency and content of QC, (3) availability of FDG, (4) injection method, (5) injected dose, (6) uptake duration, (7) data acquisition mode, (8) scan duration, (9) availability of list mode, (10) image reconstruction method, (11) image reconstruction parameters, (12) history of phantom experiments, and (13) evaluation of phantom experiment results. Body phantoms and 18 F-solution have been used in experiments involving acquisition of PET data on a simulated torso of the human body with varying scan duration. The obtained images were both physically and visually evaluated. Phantom background activity concentration is controlled at 2.65 kBq/mL and the hot sphere activity is controlled at four times the background activity. Emission scan duration is 12 min with 3D list-mode acquisition. When the list mode is not available, the default acquisition duration used in the clinical PET/CT examinations is used to acquire the data. The phantom noise equivalent count (NEC phantom ), visualization of the 10-mm sphere (visual score), image noise (N 10mm ), % contrast (Q H,10mm /N 10mm ), and relative recovery coefficient (RC) are evaluated.
Imaging protocol CT may be performed for attenuation correction of emission images and localization of positive lesions. The need for additional diagnostic information should be weighed against the increased radiation exposure from CT. Dose parameters should be consistent with the ALARA (as low as reasonably achievable) principle. Emission images of the axial skeleton may begin as soon as 30-45 min after administration of 18 F-fluoride, because of the rapid localization of 18 F-fluoride in the skeleton and its rapid clearance from the circulation. High-quality images will be obtained with a start time of 90-120 min for whole-body imaging. Images can be acquired in two-or three-dimensional mode, but the three-dimensional mode is recommended for whole-body imaging because the higher count rates compensate for the shorter acquisition times required for whole-body imaging [26] .
Acquisition time per bed position will vary depending on the amount of injected radioactivity, decay time, body mass index, and camera factors [6] . Widely used acquisition times are 2-5 min per bed position. Favorable images of the axial skeleton may be obtained with an acquisition time of 3 min/bed position starting 45 min after injection of 185 MBq (5 mCi) of 18 F-fluoride. Whole-body images can be obtained with an acquisition time of 3 min/ bed position starting 2 h after injection of 370 MBq (10 mCi) of 18 F-fluoride according to the guideline [26] . The optimal number of iterations and subsets, filters, and other reconstruction parameters will depend on patient and camera factors.
Image interpretation criteria 18 F-fluoride uptake that is visibly higher or lower than uptake in adjacent bone, or uptake in the corresponding contralateral region, indicates an alteration in bone metabolism (Figs. 1, 2 ). Physiological accumulation of 18 F-fluoride occurs in the entire skeleton, urinary tract, and soft tissues. 18 F-fluoride uptake in the skeleton is generally uniform in adults. Normal growth causes increased localization in the metaphyses of children and adolescents. Symmetric uptake between the left and right sides is generally observed in individuals of all ages. Soft-tissue accumulation reflects the amount of circulating 18 F-fluoride in the blood pool at the time of imaging. Local or regional hyperemia may cause increased visualization of the soft tissues. 18 F-fluoride localization in the skeleton is dependent on regional blood flow, as well as on the surface of new bone. 18 F-fluoride uptake is higher in new bone (osteoid) because of the higher availability of binding sites [6] . Correlation with skeletal roentgenograms and other anatomical imaging is essential for diagnosis. Asymmetric periarticular 18 F-fluoride uptake is observed in subclinical joint disease.
18 F-fluoride PET or PET/CT images are assessed for the presence of bone metastases using a fivepoint grading system. Images are scored from 0 to 4 (0 = definitely negative, 1 = probably negative, 2 = possibly positive, 3 = probably positive and 4 = definitely positive) for each individual lesion [31] . Thus, grade 3 or 4 lesions on PET or PET/CT are considered to be suspected bone metastases. The use of quantitative indices, such as standardized uptake value and kinetic model parameters K1-K4, has not been validated. The clinical relevance of quantitative indices is undefined. Accurate interpretation requires correlation with other information including clinical history, symptoms, prior imaging studies, and other diagnostic tests.
Eligibility of data sources for meta-analysis
Two additional articles have become available for analysis since the publication of our previous meta-analysis study [32] . In this article, we update our previous meta-analysis data. The Medline (from 1966 to November, 2012), SCOPUS, and Biological Abstracts databases were searched using a search algorithm based on combinations of the 18 F-fluoride PET/CT, (2) bone scintigraphy, (3) bone metastasis, metastatic bone tumor, without language restriction. Reviewers independently assessed potentially relevant citations for inclusion, and disagreements were resolved by consensus. Articles referenced in the retrieved studies were screened to identify additional studies. The investigators of eligible studies were contacted and asked to provide supplementary data when information relevant to the meta-analysis was missing. We excluded studies with verification bias, including patients with non-solid tumors such as hematological malignancies. Studies assessing by 18 F-FDG alone or BS alone, and those not making comparisons with 18 Ffluoride, were excluded. Studies using 18 F-fluoride PET or PET/CT, or BS for evaluation of status after treatment including recurrence were excluded. Studies that contained patients whose disease was not diagnosed in accordance with the reference standard, regardless of information provided by the author, or who presented concomitant diseases were excluded. We also excluded case reports, case series without precise data descriptions regarding the type and number of patients, and studies without descriptions regarding the definition of positive test results.
Data extraction
The following data were collected: author names, journal, year of publication, country of origin, number of patients, age of patients, inclusion and exclusion criteria, study design, injected dose, imaging camera, imaging technical characteristics and protocol, data type (patient-or lesionbased), number of reviewers who assessed and interpreted the results of the imaging, definition of positive test results (qualitative or quantitative), and reference standard. The number of true-positive, false-positive, true-negative, falsenegative, and equivocal findings for each modality were also recorded considering both patient-and lesion-based data. Several studies contained accurate data for 18 F-fluoride PET or PET/CT, as well as for BS. Therefore, we also evaluated the accuracy of 18 F-fluoride PET or PET/CT, BS and/or BS/SPECT, where these data were available. Imaging modalities other than 18 F-fluoride PET or PET/ BS bone scintigraphy, SPECT single-photon emission computed tomography, PET positron emission tomography, pt patient, TP true positive, FP false positive, TN true negative, FN false negative, EQ equivocal, NA not applicable CT, BS and/or BS/SPECT were not considered in the statistical analyses.
Results of the meta-analysis
Our literature search yielded 36 articles; 22 were excluded after reading the abstracts because they did not contain any diagnostic information. Thus, 14 articles, representing a total of 563 patients [31, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] , were available for our analysis. Of these 14 studies, nine contained patient-based data for planar BS or planar BS plus SPECT and 12 contained patient-based data for Tables 1, 2 and 3 summarize the data regarding the imaging technical characteristics and inclusion and exclusion criteria. Three of the 14 studies (21 %) were performed using only 18 Ffluoride PET or PET/CT without comparison with planar BS or planar BS plus SPECT. Six of the 14 studies (43 %) were stratified by histology of the primary tumor: lung carcinoma in three studies, prostate carcinoma in two, and head and neck cancer in one. Five studies (36 %) stated that they were prospective. All the papers reported that evaluation of the study results had been done in a qualitative manner, whereas one study stated explicitly that evaluation had also been performed by a quantitative method using active ratio of lesion. The reference standard consisted of other imaging studies including CT, MRI, radiography, 18 F-FDG PET, clinical follow-up, and biopsy. However, one study did not comment on the reference standard method. The corresponding author of that study was contacted and we were informed that follow-up CT and MRI were used as reference standard. 
Cost-effectiveness
In all the extracted studies, cost-effectiveness was compared between each modality: planar BS and/or SPECT, 18 F-fluoride PET, and 18 F-fluoride PET/CT. The expected effectiveness was defined as the proportion of correctly diagnosed patients. Direct costs were considered from the perspective of Japanese and American hospitals. Expected costs were calculated in US$ for 2012, based on the CMS Medicare rates for BS. Since 18 F-fluoride is not reimbursed by Japanese insurance and CMS Medicare or private payers in the US, hospital charges for 18 F-FDG PET or PET/CT were estimated based on the published ranges of official charges and CPT codes. Average cost-effectiveness ratios were calculated by dividing expected costs by the expected effectiveness, which corresponded to the accuracy of literature studies [32] , and expressed in US$ and Euro (EUR) applying the exchange rate as of November 13, 2012 . The average cost per study in the US was estimated based on the published ranges of CPT codes. For 18 F-fluoride PET or PET/CT, the average cost per study ranged from 1,000 US$ to 1,500 US$. The average cost-effectiveness ratio ranged from 1,038 to 1,558 US$ (1,298 EUR to 1,948 EUR). Similarly, the average cost per study, based on the CMS Medicare rates, was 297 US$ for planar BS or planar BS plus SPECT. The average cost-effectiveness ratio would be 404 US$ (505 EUR) per study for planar BS or planar BS plus SPECT.
Conclusions
This meta-analysis allowed us to investigate how 18 Ffluoride PET or PET/CT can contribute to the diagnosis of metastatic bone tumor. Planar BS or planar BS plus SPECT appear to have limited sensitivity but similar specificity to detect metastatic bone tumor both on a patient and on a lesion basis. The question of whether there is an incremental diagnostic improvement with 18 F-fluoride PET or PET/CT for bone metastasis needs to be addressed in further studies, as do the issues of radiation dose, cost-effectiveness, and potential complications against the yield of information. 
